Multifactorial Genesis of Pancreatitis in Primary Hyperparathyroidism: Evidence for “Protective” (PRSS2) and “Destructive” (CTRC) Genetic Factors

 

 Buy Article Permissions and Reprints

Abstract

Objective: A relationship between primary hyperparathyroidism (pHPT) and pancreatitis has long been debated and remains a rare epiphenomenon. In a cohort of patients with pHPT and pancreatitis mutations in the serine protease inhibitor Kazal type I (SPINK1) and cystic fibrosis transmembrane conductance regulator (CFTR) genes, that increase the risk for pancreatitis have already been detected. Among the identification of additional pancreatitis-associtated mutations in the Chymotrypsin C gene (CTRC) it became clear that also protective genetic variants exist in the anionic trypsinogen gene (PRSS2) that decrease susceptibility for pancreatitis. Our aim was to detect either protective or inducing genetic factors in a large cohort of pHPT patients.

Methods: Among 1 259 patients with pHPT, 57 patients were identified with pancreatitis (4.5%). DNA was available from 31 patients (16 acute pancreatitis/15 chronic pancreatitis). These individuals and 100 patients with pHPT without pancreatitis were analysed for CTRC (p.R254W and p.K247_R254del) and PRSS2 (p.G191R) mutations using melting curve analysis and DNA sequencing or PCR and gel electrophoresis (in case of p.K247_R254del CTRC).

Results: 2 of 31 patients with pHPT and pancreatitis carried the CTRC p.R254W missense mutation (6.5%), while all 100 pHPT controls without pancreatitis showed no CTRC mutation (P=0.055). No further SPINK1 p.N34S (n=4) mutations were detected but the probability of either CTRC or SPINK1 mutations in pHPT patients with pancreatitis is high (P<0.05). 1 patient was trans-heterozygous (SPINK1: N34S/CTRC p.R254W). CTRC p.K247_R254del was not detected in both groups. PRSS2 (p.G191R) mutation was present in 1 patient with pancreatitis (3.2%) and in 6 pHPT controls (6%) (P=1).

Conclusion: This study underlines the relevance of a genetic background in pHPT related pancreatitis. However, it only indicates that the CTRC (p.R254W) mutation might also contribute to the panel of mutations (SPINK1 and CFTR) that have been formerly reported to elevate pancreatitis susceptibility in pHPT. Besides it suggests that protective genetic variants, i. e., p.G191R PRSS2, may contribute to the low prevalence of pancreatitis in pHPT patients.

References

• 1 Felderbauer P, Karakas E, Fendrich V. et al . Pancreatitis risk in primary hyperparathyroidism: Relation to mutations in the spink1 trypsin inhibitor (N34S) and the cystic fibrosis gene.  Am J Gastroenterol. 2008;  103 368-374
  Google Scholar
• 2 Sutton R, Criddle D, Raraty MG. et al . Signal transduction, calcium and acute pancreatitis.  Pancreatology. 2003;  3 497-505
  Google Scholar
• 3 Felderbauer P, Karakas E, Fendrich V. et al . Pancreatitis in primary hyperparathyroidism-related hypercalcaemia is not associated with mutations in the casr gene.  Exp Clin Endocrinol Diabetes. 2007;  115 527-529
  Google Scholar
• 4 Rosendahl J, Witt H, Szmola R. et al . Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis.  Nat Genet. 2008;  40 78-82
  Google Scholar
• 5 Rinderknecht H, Adham NF, Renner IG. et al . A possible zymogen self-destruct mechanism preventing pancreatic autodigestion.  Int J Pancreatol. 1988;  3 33-44
  Google Scholar
• 6 Szmola R, Sahin-Toth M. Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with rinderknecht's enzyme y.  Proc Natl Acad Sci USA. 2007;  104 11227-11232
  Google Scholar
• 7 Tomomura A, Yamada H, Fujimoto K. et al . Determination of amino acid sequence responsible for suppression of bone resorption by serum calcium-decreasing factor (caldecrin).  FEBS Lett. 2001;  508 454-458
  Google Scholar
• 8 Tomomura A, Fukushige T, Noda T. et al . Serum calcium-decreasing factor (caldecrin) from porcine pancreas has proteolytic activity which has no clear connection with the calcium decrease.  FEBS Lett. 1992;  301 277-281
  Google Scholar
• 9 Tomomura A, Fukushige T, Tomomura M. et al . Caldecrin proform requires trypsin activation for the acquisition of serum calcium-decreasing activity.  FEBS Lett. 1993;  335 213-216
  Google Scholar
• 10 Witt H, Sahin-Toth M, Landt O. et al . A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis.  Nat Genet. 2006;  38 668-673
  Google Scholar
• 11 Etemad B, Whitcomb DC. Chronic pancreatitis: Diagnosis, classification, and new genetic developments.  Gastroenterology. 2001;  120 682-707
  Google Scholar
• 12 Sahin-Toth M. Biochemical models of hereditary pancreatitis.  Endocrinol Metab Clin North Am. 2006;  35 303-312 ix
  Google Scholar
• 13 Bess MA, Edis AJ, van Heerden JA. Hyperparathyroidism and pancreatitis. Chance or a causal association?.  JAMA. 1980;  243 246-247
  Google Scholar
• 14 van Lanschot JJ, Bruining HA. Primary hyperparathyroidism and pancreatitis.  Neth J Surg. 1984;  36 38-41
  Google Scholar
• 15 Koppelberg T, Bartsch D, Printz H. et al . [pancreatitis in primary hyperparathyroidism (phpt) is a complication of advanced phpt].  Dtsch Med Wochenschr. 1994;  119 719-724
  Google Scholar
• 16 Carnaille B, Oudar C, Pattou F. et al . Pancreatitis and primary hyperparathyroidism: Forty cases.  Aust N Z J Surg. 1998;  68 117-119
  Google Scholar
• 17 Agarwal A, George RK, Gupta SK. et al . Pancreatitis in patients with primary hyperparathyroidism.  Indian J Gastroenterol. 2003;  22 224-225
  Google Scholar
• 18 Sherwood MW, Prior IA, Voronina SG. et al . Activation of trypsinogen in large endocytic vacuoles of pancreatic acinar cells.  Proc Natl Acad Sci USA. 2007;  104 5674-5679
  Google Scholar
• 19 Santhosh S, Witt H, te Morsche RH. et al . A loss of function polymorphism (G191R) of anionic trypsinogen (PRSS2) confers protection against chronic pancreatitis.  Pancreas. 2008;  36 317-320
  Google Scholar

Correspondence

P. FelderbauerMD 

Department of Medicine I

St. Josef-Hospital

Ruhr-University of Bochum

Gudrunstraße 54

44791 Bochum

Germany

Phone: +49/0234/509 2378

Fax: +49/0234/509 2396

Email: peter.felderbauer@rub.de